| abstract |
Claim 1: A pharmaceutical composition characterized in that it comprises (a) metformin or a pharmaceutically acceptable salt thereof in an amount ranging from 100 mg to 2000 mg; and (b) a compound of formula (1) wherein ring A is a moiety of formula (2) wherein R¹ᵃ is a halogen atom, a C₁₋₄ alkyl group, or a C₁₋₄ alkoxy group, and R²ᵃ and R³ᵃ are hydrogen atoms; and ring B is a moiety of formula (3) wherein R⁴ᵃ is a phenyl group optionally substituted with a substituent selected from the group consisting of a halogen atom, a cyano group, a C₁₋₄ alkyl group, a halo- C₁₋₄ alkyl, a C₁₋₄ alkoxy group, a halo-C₁₋₄ alkoxy group, a mono- or di-C₁₋₄ alkylamino group, a carbamoyl group, and a mono- or di-C₁₋₄ alkylcarbamoyl group; or a heterocyclyl group optionally substituted with a halogen atom, a cyano group, a C₁₋₄ alkyl group, a C₁₋₄ alkoxy group, a carbamoyl group, or a mono- or di-C₁₋₄alkylcarbamoyl group, and R⁵ᵃ is a hydrogen atom; and Y is -CH₂-; or a pharmaceutically acceptable salt thereof; in an amount of from 10 mg to 300 mg; and between 5% and 50% by weight of diluent selected from the group consisting of lactose, microcrystalline cellulose, dicalcium phosphate, and starch; between 1% and 10% by weight of binder selected from the group consisting of polyvinylpyrrolidone, methylcellulose, hydroxypropyl cellulose, and hydroxypropyl methylcellulose; and between 1% and 10% by weight of disintegrant selected from the group consisting of sodium starch glycolate, croscarmellose sodium, and crospovidone. |